This is an ongoing project in clinical research in breast cancer with the long-term goal of improving hormonal treatment of breast cancer. The principal imaging tool for this Project will continue to be PET ER imaging using [F-18]-fluoroestradiol (FES), and the proposed studies follow directly from our work in the current funding period showing heterogeneous ER expression in breast tumors. We will now test approaches to evaluate factors affecting response. The focus of our proposed studies will be patients with recurrent or metastatic breast cancer from an ER+ primary tumor who are being considered for treatment with aromatase inhibitors, the hormonal therapy of choice for this patient population. In this group of patients, where biopsy is difficult because of multiple or inaccessible sites of disease, imaging can identify therapeutic targets and play a significant role in directing therapy.
Our specific aims are to (1) determine the ability of FES PET imaging to predict patient's response to hormonal therapy, (2) determine the early response to hormonal therapy by measuring the change in receptor occupancy and tumor proliferation early in the course of treatment, and (3) determine the relationship between ER expression and the abnormal expression of other growth factor receptors, specifically HER2 and EGFR, and their relationship to response to hormonal therapy. These studies will lead directly to clinical paradigms using PET imaging data with tumor-specific receptor ligands to make individualized choices of therapy in patients. The studies will also identify which mechanisms of resistance to hormonal therapy are clinically important and help direct efforts to overcome resistance to hormonal treatment of breast cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Washington
United States
Zip Code
O'Sullivan, Finbarr; O'Sullivan, Janet N; Huang, Jian et al. (2018) Assessment of a statistical AIF extraction method for dynamic PET studies with 15O water and 18F fluorodeoxyglucose in locally advanced breast cancer patients. J Med Imaging (Bellingham) 5:011010
Linden, Hannah M; Peterson, Lanell M; Fowler, Amy M (2018) Clinical Potential of Estrogen and Progesterone Receptor Imaging. PET Clin 13:415-422
Lindner, Jonathan R; Link, Jeanne (2018) Molecular Imaging in Drug Discovery and Development. Circ Cardiovasc Imaging 11:e005355
Link, Jeanne M; Krohn, Kenneth A; O'Hara, Matthew J (2017) A simple thick target for production of89Zr using an 11MeV cyclotron. Appl Radiat Isot 122:211-214
Wolsztynski, E; O'Sullivan, F; O'Sullivan, J et al. (2017) Statistical assessment of treatment response in a cancer patient based on pre-therapy and post-therapy FDG-PET scans. Stat Med 36:1172-1200
Kurland, Brenda F; Peterson, Lanell M; Lee, Jean H et al. (2017) Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer. Clin Cancer Res 23:407-415
Wangerin, Kristen A; Muzi, Mark; Peterson, Lanell M et al. (2017) A virtual clinical trial comparing static versus dynamic PET imaging in measuring response to breast cancer therapy. Phys Med Biol 62:3639-3655
Fowler, Amy M; Clark, Amy S; Katzenellenbogen, John A et al. (2016) Imaging Diagnostic and Therapeutic Targets: Steroid Receptors in Breast Cancer. J Nucl Med 57 Suppl 1:75S-80S
Muzi, Mark; Krohn, Kenneth A (2016) Imaging Hypoxia with ยน?F-Fluoromisonidazole: Challenges in Moving to a More Complicated Analysis. J Nucl Med 57:497-8
Currin, Erin; Peterson, Lanell M; Schubert, Erin K et al. (2016) Temporal Heterogeneity of Estrogen Receptor Expression in Bone-Dominant Breast Cancer: 18F-Fluoroestradiol PET Imaging Shows Return of ER Expression. J Natl Compr Canc Netw 14:144-7

Showing the most recent 10 out of 196 publications